Corona: What measures have Governments taken in the Life Sciences Sector?
Register now for ECA's GMP Newsletter
Governments have been implementing different emergency measures in the fight against the current pandemic. The Baker McKenzie Healthcare and Life Sciences Industry Group has now published an interesting overview of the different measures that various governments across the EMEA region (Europe, Middle East, Asia) have adopted in the area of healthcare and life sciences in response to the COVID-19 outbreak.
In this document, Baker McKenzie lawyers across EMEA share their high-level views on the following areas:
- Requisition powers
- Price and reimbursement
- Public procurement
- Legal deadlines
- Relaxation of regulatory rules
Related GMP News
25.06.2025Is Knowledge Management a Part of the Pharmaceutical Quality System?
11.06.2025Swissmedic differentiates GMP Scope for Manufacturing and Preparation for Administration
28.05.2025A View on the EU Critical Medicines Act to secure Pharma Supply Chains
20.05.2025Summary Data on Registration and Listing of Cosmetic Facilities and Products
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review